Announcements

Jan 30, 2017 - Eligo will be presenting at the 19th Annual Superbugs & Superdrugs, London | 20–21 Mar 2017
Jan 30, 2017 – Eligo will be presenting at the 19th Annual Superbugs & Superdrugs, London | 20–21 Mar 2017
Jan 15, 2017 - Eligo will be presenting at the SACHS 10th European Life Science CEO Forum, Zurich | 5-6 Mar 2017
Jan 15, 2017 – Eligo will be presenting at the SACHS 10th European Life Science CEO Forum, Zurich | 5-6 Mar 2017
Jan 13, 2017 - Eligo's CEO listed among the ``30 Under 30 in Science and Healthcare`` by Forbes
Jan 13, 2017 – Eligo’s CEO listed among the “30 Under 30 in Science and Healthcare” by Forbes
Sept 20, 2016 - Eligo Bioscience is awarded 2 highly selective grants by the French National Research Agency
Sept 20, 2016 – Eligo Bioscience is awarded 2 highly selective grants by the French National Research Agency
May 31, 2016 - JP Lehner, former Chief Medical Officer at Sanofi, joins Eligo Bioscience
Eligo Bioscience is proud to welcome Jean-Pierre Lehner as a new board member.  Jean-Pierre Lehner, M.D., used to serve as the Senior Vice-President, Chief Medical Officer from 2009 to 2015 and before that Senior Vice President, Medical & Regulatory Affairs at Sanofi.

Jean-Pierre Lehner holds a Medical degree from the School of Medicine University of Paris, France. After spending four years as Chef de Clinique, assistant of Paris Hospitals, Department of Cardiology (Pr Tricot), Hôpital Bichat, Paris, France, Jean-Pierre Lehner joins Roussel Laboratories in 1981 as Medical Director (1981-1986), then he is named Medical Director of Roussel-Uclaf (1986-1992). He is successively Senior Director of Clinical Investigations of Sanofi Recherche (1992-1996), Scientific Senior Director of Sanofi Winthrop (1996-2002), Vice President Medical Affairs Europe of sanofiaventis (2003-2005). As from 2005, Jean-Pierre Lehner was Senior Vice-President, Medical & Regulatory Affairs sanofi-aventis.

July 8, 2015 - Eligo closes a €2M seed-funding round with Seventure Partners
Eligo Bioscience, a spin-off from Massachusetts Institute of Technology (MIT) and Rockefeller University, announced today it received an investment of €2m in a seed round financing from Seventure, one of Europe’s leaders in financing innovation and visionary investor in the microbiome field since 2008. Business angels will also join the round during the summer. Press release here (French version here)
February 9, 2015 - Eligo is a laureate of the Tremplin Entreprises 2015 edition
Eligo Bioscience is laureate of the national startup competition Tremplin Entreprises organised by ESSEC and the French Senate and received € 5,000 in non-dilutive funding. Read more…
July 17, 2014 – Eligo is a laureate of the Concours National de Création d’Entreprises Innovantes
Eligo is a laureate of the French national startup competition (Emergence category) and receives €31,000 in non-dilutive funding. Read more…
June 8, 2014 – Eligo is a laureate of the Worldwide Innovation Challenge
Eligo Bioscience (previously PhageX) is one of 19 biotech projects selected among 630 candidates for the first phase of the Worldwide Innovation Competition and received € 200,000 in non-dilutive funding.
Recently launched by the French Government, this competition aims to finance the most promising international companies in 7 industrial sectors. Read more…
June 8, 2014 – Eligo is a laureate of the Worldwide Innovation Challenge
Eligo Bioscience (previously PhageX) is one of 19 biotech projects selected among 630 candidates for the first phase of the Worldwide Innovation Competition and received € 200,000 in non-dilutive funding.
Recently launched by the French Government, this competition aims to finance the most promising international companies in 7 industrial sectors. Read more…

International Press

Feb 16, 2017 - Science

Read article here

Jan 9, 2017 - Bloomberg

Read article here

Jan 7, 2017 - Huffington Post

Read article here

June 6, 2016 - Vice

Read article here

July 17, 2015 - Fierce Drug Delivery

Parisian biotech pulls in €2M to fund CRISPR delivery work

Read article here

July 16, 2015 - SynbioBeta
Eligo Bioscience Raises €2M To Develop CRISPR Antimicrobials
Read the article
July 13, 2015 - BioCentury
Seventure Partners’ latest investment from its Health for Life Capital fund aims to harness the precision of CRISPR technology to preferentially eliminate harmful bacteria from the microbiome.
Read the article
July 9, 2015 - LaBiotech.eu
Meet Eligo, the Startup which Raised €2M to Redefine Antibiotics using CRISPR

Read the article

November 5, 2014 - WIRED
Want to Kill Antibiotic-Resistant Bacteria? Forget About Antibiotics!

Read the article

September 26, 2014 – MIT News
Battling Superbug :  Two new technologies could enable novel strategies for combating drug-resistant bacteria.

Read the article

September 24, 2014 – BBC News
Novel antibiotic class created –  Scientists have designed a new class of antibiotic which seeks and destroys resistance genes in bacteria.

Read the article

September 23, 2014 – Fierce Biotech
Gene editing technique could cut away antibiotic-resistant genes.

Read the article

Previous: Nanowerk, Medical Daily, Times of India
05/10/2014 –  Nanowerk – ‘Programmable’ antibiotic harnesses an enzyme to attack drug-resistant microbes created
Read more…

05/10/2014 –  Times of India – ‘Gene editing’ to help kill superbugs. Read more…

05/10/2014 –  Medical Daily – Antibiotic-Resistant Bacteria Can’t Handle Attacks From Engineered Enzymes ‘Programmed’ To Target Them. Read more…

French Press

Oct 13, 2016 - Les Echos
Read the article
July 20, 2015 - Maddyness
#MedTech : Seventure Partners investit deux millions d’euros dans Eligo Bioscience – Seventure Partners, qui investit principalement dans les technologies numériques en France et en Allemagne et dans les sciences de la vie dans toute l’Europe, annonce un investissement de deux millions d’euros dansEligo Bioscience, qui développe des antibiotiques intelligents.
Read the article
July 9, 2015 - Les Echos
L’innovation: un atout français pour notre santé
Read the article
July 9, 2015 - L'Obs
Les antibiotiques du futur seront-ils inventés en France?
– Deux jeunes chercheurs français viennent de lever 2 millions d’euros pour financer Eligo Bioscience, dans l’espoir de résoudre le grave problème de la résistance bactérienne aux antibiotiques.
Read the article
July 9, 2015 - Industrie et Technologies
Eligo Biosciences lève 2 millions d’euros pour développer ses antibiotiques intelligents – La start-up Eligo Biosciences a mis au point des antibiotiques « intelligents ». Baptisés éligobiotiques, ils sont capables de détruire des bactéries virulentes ou résistances aux antibiotiques actuels tout en laissant intact le reste du microbiome des patients. Ces médicaments 2.0 s’appuient sur les ciseaux à ADN Crispr.

Read the article

April 22, 2015 - La Tribune
Xavier Duportet, Innovateur français de l’année pour le MIT -#FRENCHTECH – À 27 ans, ce docteur en biologie synthétique, fondateur de PhageX, une biotech qui s’attaque au marché des antibiotiques, et du Hello Tomorrow Challenge, vient d’être élu « innovateur de l’année » par la MIT Technology Review qui a récompensé la semaine dernière avec l’Atelier BNP Paribas les 10 innovateurs français de moins de 35 ans les plus remarquables. Il succède à Rand Hindi, spécialiste du Big data qui avait eu le même prix l’an dernier pour avoir créer l’appli Tranquillien. Cet article reprend le portrait de Xavier Duportet publié dans notre hebdomadaire en page Génération en janvier 2015.

Read the article

April 21, 2015 - Biotech Finances
Eligo Bioscience recherche 2 M€ pour ses éligobiotiques

Read the article

April 21, 2015 - BFM Business/TV
Eligo Bioscience a développé des antibiotiques intelligents

Watch the video

April 20, 2015 - Sciences et Avenir
Bactéries, insectes ou main bionique : l’innovation selon le MIT
Read the article
April 17, 2015 - France Inter
La tête au carrée
Listen the podcast
XavierNews